India · Delayed Price · Currency is INR Godavari Drugs Statistics
Total Valuation
Godavari Drugs has a market cap or net worth of INR 948.47 million. The enterprise value is 1.57 billion.
| Market Cap | 948.47M |
| Enterprise Value | 1.57B |
Important Dates
The last earnings date was Wednesday, May 27, 2026.
| Earnings Date | May 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Godavari Drugs has 7.53 million shares outstanding. The number of shares has increased by 1.37% in one year.
| Current Share Class | 7.53M |
| Shares Outstanding | 7.53M |
| Shares Change (YoY) | +1.37% |
| Shares Change (QoQ) | +4.93% |
| Owned by Insiders (%) | 59.86% |
| Owned by Institutions (%) | n/a |
| Float | 2.72M |
Valuation Ratios
The trailing PE ratio is 23.50.
| PE Ratio | 23.50 |
| Forward PE | n/a |
| PS Ratio | 0.89 |
| PB Ratio | 1.25 |
| P/TBV Ratio | 1.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 129.29 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 38.32 |
| EV / Sales | 1.47 |
| EV / EBITDA | 14.09 |
| EV / EBIT | 18.04 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 1.01.
| Current Ratio | 1.31 |
| Quick Ratio | 0.68 |
| Debt / Equity | 1.01 |
| Debt / EBITDA | 6.87 |
| Debt / FCF | -2.94 |
| Interest Coverage | 2.18 |
Financial Efficiency
Return on equity (ROE) is 6.86% and return on invested capital (ROIC) is 5.51%.
| Return on Equity (ROE) | 6.86% |
| Return on Assets (ROA) | 3.16% |
| Return on Invested Capital (ROIC) | 5.51% |
| Return on Capital Employed (ROCE) | 7.54% |
| Weighted Average Cost of Capital (WACC) | 5.28% |
| Revenue Per Employee | 10.06M |
| Profits Per Employee | 385,764 |
| Employee Count | 106 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 2.09 |
Taxes
In the past 12 months, Godavari Drugs has paid 9.74 million in taxes.
| Income Tax | 9.74M |
| Effective Tax Rate | 19.24% |
Stock Price Statistics
The stock price has increased by +28.72% in the last 52 weeks. The beta is 0.35, so Godavari Drugs's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +28.72% |
| 50-Day Moving Average | 119.97 |
| 200-Day Moving Average | 92.46 |
| Relative Strength Index (RSI) | 54.83 |
| Average Volume (20 Days) | 4,692 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Godavari Drugs had revenue of INR 1.07 billion and earned 40.89 million in profits. Earnings per share was 5.36.
| Revenue | 1.07B |
| Gross Profit | 291.16M |
| Operating Income | 86.88M |
| Pretax Income | 50.63M |
| Net Income | 40.89M |
| EBITDA | 111.20M |
| EBIT | 86.88M |
| Earnings Per Share (EPS) | 5.36 |
Balance Sheet
The company has 145.09 million in cash and 763.58 million in debt, with a net cash position of -618.49 million or -82.13 per share.
| Cash & Cash Equivalents | 145.09M |
| Total Debt | 763.58M |
| Net Cash | -618.49M |
| Net Cash Per Share | -82.13 |
| Equity (Book Value) | 757.99M |
| Book Value Per Share | 100.42 |
| Working Capital | 266.52M |
Cash Flow
In the last 12 months, operating cash flow was 7.34 million and capital expenditures -267.23 million, giving a free cash flow of -259.90 million.
| Operating Cash Flow | 7.34M |
| Capital Expenditures | -267.23M |
| Depreciation & Amortization | 24.32M |
| Net Borrowing | 130.76M |
| Free Cash Flow | -259.90M |
| FCF Per Share | -34.51 |
Margins
Gross margin is 27.31%, with operating and profit margins of 8.15% and 3.84%.
| Gross Margin | 27.31% |
| Operating Margin | 8.15% |
| Pretax Margin | 4.75% |
| Profit Margin | 3.84% |
| EBITDA Margin | 10.43% |
| EBIT Margin | 8.15% |
| FCF Margin | n/a |
Dividends & Yields
Godavari Drugs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.37% |
| Shareholder Yield | -1.37% |
| Earnings Yield | 4.31% |
| FCF Yield | -27.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |